Cargando…

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joharapurkar, Amit A., Patel, Vishal J., Kshirsagar, Samadhan G., Patel, Maulik S., Savsani, Hardikkumar H., Kajavadara, Chetan, Valani, Darshan, Jain, Mukul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096675/ https://www.ncbi.nlm.nih.gov/pubmed/35570856 http://dx.doi.org/10.1016/j.crphar.2022.100102

Ejemplares similares

Desidustat: First Approval
por: Dhillon, Sohita
Publicado: (2022)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)
por: Gang, Sishir, et al.
Publicado: (2022)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

“Trace” the Element: The Plausible Role Played by Selenium in the Erythropoietin Hyporesponsiveness
por: Azancot, Sarah, et al.
Publicado: (2022)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

The Predictive Parameters of Erythropoietin Hyporesponsiveness in Patients on Continuous Ambulatory Peritoneal Dialysis
por: Kim, Jeong Ki, et al.
Publicado: (2001)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
por: Harlow, Charli E, et al.
Publicado: (2022)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review
por: Damarlapally, Nanush, et al.
Publicado: (2023)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
por: Kansagra, Kevinkumar A., et al.
Publicado: (2017)

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
por: Zhang, Huifang, et al.
Publicado: (2020)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
por: Chen, Dinghua, et al.
Publicado: (2023)

Structure and Mechanism of a Viral Collagen Prolyl Hydroxylase
por: Longbotham, James E., et al.
Publicado: (2015)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

Role of prolyl hydroxylase domain proteins in bone metabolism
por: Wolf, David, et al.
Publicado: (2022)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
por: Noonan, Megan L., et al.
Publicado: (2020)

Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
por: Kant, Ravi, et al.
Publicado: (2013)

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma
por: Hatzimichael, E, et al.
Publicado: (2012)

Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein
por: Place, Trenton L, et al.
Publicado: (2013)

Role of prolyl hydroxylase domain proteins in the regulation of insulin secretion
por: Huang, Mei, et al.
Publicado: (2016)

Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
por: Yang, Ming, et al.
Publicado: (2014)

Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase
por: Yum, Soohwan, et al.
Publicado: (2017)

An Arabidopsis Prolyl 4 Hydroxylase Is Involved in the Low Oxygen Response
por: Konkina, Anna, et al.
Publicado: (2021)

Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis
por: Pignata, Paola, et al.
Publicado: (2021)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
por: Strowitzki, Moritz J., et al.
Publicado: (2021)

Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification
por: Negri, Armando Luis
Publicado: (2022)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_icmp92ef44tub4va9it3c2i20v